Gastrointestinal Cancer

Second-line ramucirumab (Cyramza) reduced the risk of death by 29% versus placebo in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein.

A combination of 2 over-the-counter medicines can moderately reduce the risk for high-grade dysplasia or esophageal cancer in patients with Barrett’s esophagus if taken for at least 7 years.

Ramesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses the treatment of patients with pancreatic cancer.

A 4-drug chemotherapy combination dramatically improved survival compared with standard gemcitabine as postoperative therapy for patients with resected pancreatic cancer.

Preoperative treatment with chemotherapy and radiation improved overall survival rates for patients with resectable or borderline resectable pancreatic cancer compared with immediate surgery.

The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis.

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

The FDA has accepted a supplemental new drug application for cabozantinib as a treatment for patients with previously-treated advanced hepatocellular carcinoma.

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.

The FDA has extended the review period for lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma. The new action date for the supplemental new drug application is August 24, 2018.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.

Diane M. Simeone, MD, discusses the molecular complexities of pancreatic cancer, some of the commonly identified mutations, and ongoing clinical trial efforts that may be game changing for the field.

Ramesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses emerging therapeutic targets in patients with pancreatic cancer.

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).

Eric A. Collisson, MD, speaks to the challenges and emerging advancements in cholangiocarcinoma and colon cancer.

Paul E. Oberstein, MD, discusses incorporating novel agents and sequencing approaches in advanced pancreatic neoplasms.

Mitesh J. Borad, MD, associate professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, discusses the results of the SARAH and SIRveNIB studies in patients with hepatocellular carcinoma.

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses the role of immunotherapy in treating patients with gastric/gastroesophageal cancers.

Combination therapy with the PD-L1 inhibitor atezolizumab and the MEK inhibitor cobimetinib failed to improve overall survival versus regorafenib in previously treated patients with locally advanced or metastatic colorectal cancer, according to topline findings from the phase III IMblaze370 study.

Findings from the phase III TAGS trial showed that TAS-102 (trifluridine/tipiracil; Lonsurf) extended overall survival in previously treated patients with metastatic gastric cancer.

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the importance of mutational analysis in the treatment of patients with pancreatic cancer.

Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.

Eric A. Collisson, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the difficulty of diagnosing cholangiocarinoma.

Paul E. Oberstein, MD, assistant professor of medicine, assistant director, Pancreatic Cancer Center, director, Gastrointestinal Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of PEGPH20 in advanced pancreatic cancer.